FARMINGDALE, N.Y., Oct. 24, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has announced its participation in the 27th Annual NASS Meeting, being held in Dallas, Texas, October 24-26, 2012.
The North American Spine Society ("NASS"), which is based in suburban Chicago, is dedicated to education, research and treatment of all types of abnormal spine conditions. NASS has upwards of 7,000 members, including more than 4,000 surgeons who dedicate more than 50% of their practice to spine surgery. It is expected that more than 3,500 members will attend the annual meeting and exhibition.
As an industry sponsor of NASS, Misonix will be exhibiting and demonstrating its innovative BoneScalpel Ultrasonic Bone Cutting System, which is gaining acceptance with spine surgeons worldwide. At the meeting, the Company will be introducing to the U.S. market three line extensions: a 30mm Blade designed for precisely transecting larger bones, a 20mm Long Curved Blade for providing deeper access into body cavities, and a Diamond Macro Shaver for rapid shaping or de-bulking of bone.
Consistent with the scientific theme of the meeting, an abstract of a white paper documenting his positive clinical experience with 128 spine surgery patients, authored by Isador H. Lieberman, M.D., MBA, FRCSC, will be released to his NASS colleagues. Dr. Lieberman is an orthopedic surgeon at the Scoliosis & Spine Tumor Center, Texas Back Institute and Texas Health Presbyterian Hospital in Plano, Texas. Dr. Lieberman has said, "The ultrasonic BoneScalpel allows me to perform a more precise and less traumatic osteotomy for my spinal deformity surgeries. I have used it in over 60 cases so far, and with each procedure I am learning more about its utility in enhancing the precision of spine surgery. It has become my standard tool for advanced bone dissections. Using the blade, I was able to revise a previous lumbar-thoracic fusion. What would have taken me 45-60 minutes per spinal level was completed in less than 10 minutes per level by using the BoneScalpel ultrasonic osteotome."
In addition, the Company's BoneScalpel System will be featured in a NASS bio-skills course entitled "Cervical Spine - Advanced Techniques," which will be held in their mobile "Surgical Training Institute" located in the exhibit hall. A guest faculty member for Misonix will be Dr. Nicholas Qandah, a practicing neurosurgeon, who is the Director of Complex Spine, Associate Residency Program Director, and Assistant Professor of Neurosurgery at Virginia Tech University/Carilion Clinic in Roanoke, Virginia, and a Professor of Neurosurgery at the Virginia College of Osteopathic Medicine, also, in Roanoke. Dr. Qandah will be providing 'hands on' instruction to his spine surgeon colleagues.
The BoneScalpel is a novel ultrasonic osteotome used for safe, tissue-selective bone dissection that encourages en-bloc bone removal and refined osteotomies while sparing elastic soft tissue structures. Most users report that the surgical field is relatively bloodless and clean. Loss of viable bone is minimal and controllable. The BoneScalpel has been used extensively for bone removal in the cervical, thoracic and lumbar spine, including deformity surgery.
"We are thrilled to be part of this meeting of world renowned experts in advanced spinal surgery," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We are privileged to demonstrate our state-of-the-art technology at this prestigious meeting, particularly in concert with Dr. Qandah at the "Cervical Spine Advanced Techniques" course, which will clearly demonstrate the clinical value associated with the Misonix BoneScalpel."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.